Abstract:Background and purpose:Single drug of docetaxel and pemetrexed as second line treatment is standard treatment of advanced non-small cell lung cancer (NSCLC). Whether combined with platinum can increase the response and survival is still not elucidated. This study was designed to investigate the treatment response, overall survival (OS) and the safety of combined with oxaliplatin or cisplatin regimens as second line in treating NSCLC patients. Methods:Advanced NSCLC inpatients, failure of cisplatin or carboplatin in initial treatment, were divided into three groups at random in 3∶2∶1 rate. Control group:who received docetaxel, 75 mg/m2 (for all patients), d1 or pemetrexed 500 mg/m2 (for non-squamous carcinoma);Cisplatin group:who received cisplatin 25 mg/m2, d1-3 and docetaxel/pemetrexed; Oxaliplatin group: who received oxaliplatin 130 mg/m2 d1 and docetaxel/pemetrexed. Every 3 weeks were repeated as one cycle. The side effect was assessed every cycle and treatment efifcacy was investigated every two cycles. Follow-up examination was taken every 3 months after treatment. Results:There were no differences in treatment response, progress free survival (PFS), OS and toxicity among the three groups (P>0.05). Old patients (≥60 years) had a better PFS than that of patients less than 60 years (HR=0.56, 95%CI:0.35-0.90, P=0.015). Patients with performance score 0-1 had a better PFS and OS (HR=1.52, 95%CI:1.01-2.30, P=0.048;HR=1.90, 95%CI:1.17-3.09, P=0.009). Treatment response had relation to PFS and OS (HR=2.93, 95%CI:2.01-4.26, P=0.000;HR=2.03, 95%CI:1.37-3.01, P=0.000). Patients with anemia after treatment tended to have a worse PFS and OS (HR=1.59, 95%CI:0.97-2.61, P=0.066;HR=1.60, 95%CI:0.94-2.75, P=0.085). Patients with thrombocytopenia after therapy had a worse OS (HR=2.97, 95%CI:1.01-8.78, P=0.049). Patients with neural toxicity after chemotherapy tended to have a worse PFS (HR=3.36, 95%CI:0.92-12.25, P=0.066). Patients received post treatment after second line therapy had a better OS (HR=0.36, 95%CI:0.22-0.61, P=0.000). Conclusion:Combined with oxaliplatin or cisplatin as second line treatment can’t improve the response and survival in NSCLC patient. Treatment response and PS are prognostic factors to NSCLC patients’ PFS and OS. Patients with treatment related anemia might have a worse survival. Post therapy after failure to second line chemotherapy can prolong the survival.

The clinical observation of gemcitabine combined with cisplatin as second-line chemotherapy for non-small cell lung cancer

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Gemcitabine Plus Cisplatin Combination in the Treatment of 16 Cases with Advanced Non Small Cell Lung Cancer

Efficacy of Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

[A Clinical Study on the Combination of Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer].

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Clinical Efficacy of Toremifene Combined with Second Line Drugs Novelbine/cisplatin on Advanced Non-Small Cell Lung Cancer

Clinical observation of docetaxel combined with oxaliplatin as the second-line therapy in advanced NSCLC

Combined with oxaliplatin or cisplatin in second line treatment of advanced non-small cell lung cancer

Gemcitabine Combined with Vinorelbine in the Treatment of Refractory Patients with Advanced Non-small Cell Lung Cancer: A Multi-center Retrospective Study

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Vinorelbine in the Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc).

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Gemcitabine and Ifosfamide As a Second-Line Treatment for Cisplatin-Refractory Metastatic Urothelial Carcinoma: a Phase II Study

Chemotherapy Based on Regimes of Gemcitabine Plus Cisplatin or Vinorelbine Plus Cisplatin in Patients with Advanced NSCLC

Comparasion on Two Combination Regimens of Nedaplatin Plus Gemcitabine and Cisplatin Plus Gemcitabine for Treatment of Patients with Advanced Non Small-cell Lung Cancer